The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

Part of paid clinical trials in New Orleans, Louisiana.

Sponsor
Tulane University
Study ID
NCT04007276
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Droopy Eyelid
  • Glaucoma
  • Glaucoma, Open-Angle
  • Glaucoma, Primary Open Angle
  • Glaucoma; Drugs
  • Ptosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • brimonidine tartrate ophthalmic solution 0.025% — DRUG
    Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
  • sterile balanced saline solution — OTHER
    Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.

Study Details

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

Key Dates

Start date
Nov 10, 2026
Status verified
Sep 2025
Primary completion
Jun 1, 2031
Completion
Jun 1, 2036

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Lumify Arm
    In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
  • Sham Comparator: Control Arm
    In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.

Primary Outcome Measure

Ocular redness [ Time Frame: 5 minutes after application of eye drop ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Tulane University Medical CenterNew OrleansLouisiana70112
Ze Zhang, MD
[email protected]
504-988-5831
Ze Zhang, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Orleans, LA

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Tulane University Medical Center· New Orleans, LA

Related Studies